最新ADHD藥物研究 Updated ADHD medication Research
"這個充滿資訊的線上講座，將為你提供專注力失調過動活躍症藥物治療領域，最新研究和發展的寶貴見解。
專注力失調過動活躍症是一種常見的神經發育障礙，及時識別並適當治療專注力失調過動活躍症可以顯著改善長期的發育結果。然而，全球專注力失調過動活躍症藥物使用的趨勢仍不清楚。
在這次的線上講座中，講者將分享他的國際研究團隊對長期使用甲基苯丙胺（MPH）-一種常用的專注力失調過動活躍症藥物，及其對患者發展和精神或神經不良風險影響的研究結果。
這個線上講座對醫學專業人員、教育工作者、父母，以及任何有興趣進一步了解專注力失調過動活躍症及其治療的人來說，都是一個絕佳的機會。從領域的領先專家那裡獲得見解，並及時瞭解專注力失調過動活躍症藥物治療領域的最新研究。立即報名，並加入我們這次的啟發性講座！"
"This informative session will provide valuable insights into the latest research and developments in the field of ADHD medication.
ADHD is a common neurodevelopmental disorder, Timely identification and appropriate treatment of ADHD can significantly improve long-term developmental outcomes. However, the global trends in the use of ADHD medications remain unclear. In this webinar, Professor Wong will share the findings of his international research team on the long-term use of Methylphenidate (MPH), a commonly prescribed ADHD medication, and its impact on patient development and risk of psychiatric or neurological adverse events.
This webinar is an excellent opportunity for medical professionals, educators, parents, and anyone interested in understanding ADHD and its treatment better. Gain insights from a leading expert and stay updated on the latest research in the field of ADHD medication. Secure your spot today and join us in this enlightening discussion!"
黃志基教授除了擔任香港大學藥理及藥劑學系系主任，還於香港政府重點項目InnoHK旗下的「醫衛大數據深析實驗室」擔任首席科學家。他與六十多位研究員組成科研團隊，跟世界各地的學術機構，甚至國際衞生機構合作。
黃教授除了利用大數據研究「專注力不足/過度活躍症」藥物在全球使用的情況外，亦分析新冠疫苗的安全性。2022年，黃教授更獲頒行政長官社區服務獎狀，表揚他在抗疫方面的貢獻。
Professor Ian Wong, Head of the Department of Pharmacology and Pharmacy at the University of Hong Kong, pursued his pharmacy studies in the UK where he successfully developed the first paediatric oral antiepileptic drug to receive a European Union Paediatric Use Marketing Authorisation. After spending over 20 years in the UK, Professor Wong decided to return to Hong Kong in 2011. He has a profound passion for teaching and has been conducting various research using medical big data and clinical trial methodologies.
In addition to his role at the University of Hong Kong, Professor Wong also serves as the Chief Scientist at the "Healthcare and Big Data Analysis Laboratory", a key project under the Hong Kong government's InnoHK initiative. He leads a research team of over sixty members, collaborating with academic institutions worldwide and even international health organizations.
Professor Wong not only utilizes big data to study the global usage of ADHD medications but also analyzes the safety of COVID-19 vaccines. In 2022, he was awarded the Chief Executive's Commendation for Community Service, recognizing his contributions to the fight against the pandemic.
